Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.
Expert Opin Pharmacother
; 17(8): 1043-53, 2016 Jun.
Article
in En
| MEDLINE
| ID: mdl-27042990
ABSTRACT
OBJECTIVE:
To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since diagnosis as recently diagnosed (≤3 years) or chronic patients (>3 years). RESEARCH DESIGN ANDMETHODS:
Post hoc analysis of a prospective, interventional, single-arm, multicentre, open-label, 6-month study performed in 233 recently diagnosed and 360 chronic patients. MAIN OUTCOMEMEASURES:
The proportion achieving treatment response (defined as ≥20% improvement in Positive and Negative Syndrome Scale [PANSS] total score from baseline to endpoint) and maintained efficacy (defined as non-inferiority in the change in PANSS total score at endpoint [Schuirmann's test]).RESULTS:
71.4% of recently diagnosed and 59.2% of chronic patients showed a ≥20% decrease in PANSS total score (p = 0.0028 between groups). Changes in PANSS Marder factors, PANSS subscales, and the proportion of patients with a Personal and Social Performance scale (PSP) total score of 71-100 were significantly greater in recently diagnosed compared with chronic patients. PP1M was well tolerated, presenting no unexpected safety findings.CONCLUSION:
These data show that recently diagnosed patients treated with PP1M had a significantly higher treatment response and improved functioning, as assessed by the PSP total score, than chronic patients.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Schizophrenia
/
Antipsychotic Agents
/
Paliperidone Palmitate
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Observational_studies
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
En
Journal:
Expert Opin Pharmacother
Journal subject:
FARMACOLOGIA
Year:
2016
Document type:
Article
Affiliation country:
Germany